Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Quadramet
Samarium Sm 153 Lexidronam is a radiopharmaceutical agent used in the treatment of bone pain associated with metastatic cancer. It is classified as a bone-seeking radioisotope. Samarium-153 is a beta-emitting radionuclide that delivers targeted radiation to bone lesions, relieving pain and potentially reducing tumor burden.
For pain relief in patients with metastatic bone cancer.
Outcome:
Increased risk of myelosuppression
Mechanism:
Additive bone marrow suppression
Outcome:
Increased risk of bleeding
Mechanism:
Additive effects on platelet function
Outcome:
Reduced absorption of other medications
Mechanism:
Changes in stomach pH
Most likely new formulation: targeted delivery systems for increased efficacy (Year: 2028, 60% confidence)
Based on current usage and research, there is a low likelihood of changes to the regulatory status of samarium Sm 153 Lexidronam in the next 5 years.
Radiopharmaceutical, Bone-seeking agent
Radioisotope